NCT05878093 - Dupilumab in Chinese Adult Participants With CRSwNP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

September 6, 2024

Study Completion Date

November 28, 2024

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Interventions

DRUG

Dupilumab

solution for subcutaneous injection

DRUG

Placebo

solution for subcutaneous injection

DRUG

Budesonide

nasal spray (suspension)

Trial Locations (18)

100044

Investigational Site Number : 1560005, Beijing

100730

Investigational Site Number : 1560001, Beijing

200065

Investigational Site Number : 1560017, Shanghai

230001

Investigational Site Number : 1560006, Hefei

250102

Investigational Site Number : 1560016, Jinan

255036

Investigational Site Number : 1560020, Zibo

264000

Investigational Site Number : 1560009, Yantai

310003

Investigational Site Number : 1560004, Hangzhou

350005

Investigational Site Number : 1560022, Fuzhou

400016

Investigational Site Number : 1560014, Chongqing

430022

Investigational Site Number : 1560007, Wuhan

430060

Investigational Site Number : 1560021, Wuhan

434020

Investigational Site Number : 1560025, Jingzhou

510163

Investigational Site Number : 1560012, Guangzhou

610041

Investigational Site Number : 1560010, Chengdu

Unknown

Investigational Site Number : 1560011, Guangzhou

Investigational Site Number : 1560013, Qingdao

030001

Investigational Site Number : 1560018, Taiyuan